Century Therapeutics (NASDAQ: IPSC) net income
Century Therapeutics reported a net loss of $9.6m for fiscal 2025; in fiscal 2024 it reported a net loss of $126.6m. Earnings per share were −$0.14.
Fiscal 2025 is the highest of the 6 fiscal years on record for Century Therapeutics. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$9.6m | — | −8.8% | −$0.14 |
| 2024 | −$126.6m | — | −1,920.9% | −$1.61 |
| 2023 | −$136.7m | — | −6,115.1% | −$2.30 |
| 2022 | −$130.9m | — | −2,518.4% | −$2.27 |
| 2021 | −$95.8m | — | — | −$2.96 |
| 2020 | −$53.6m | — | — | −$7.16 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Century Therapeutics net income compared with its sector
By net income for its latest fiscal year, Century Therapeutics ranks 190th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Century Therapeutics, −8.8%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 188th | Bruker | −$8.6m | −0.3% |
| 189th | Cronos Group | −$9.4m | −4.9% |
| 190th | Century Therapeutics | −$9.6m | −8.8% |
| 191st | Fennec Pharmaceuticals | −$9.7m | −21.8% |
| 192nd | Anika Therapeutics | −$10.9m | −9.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Century Therapeutics
- How much did Century Therapeutics earn in fiscal 2025?
- Century Therapeutics reported a net loss of $9.6m for fiscal 2025. In fiscal 2024 it reported a net loss of $126.6m.
- What are the earnings per share of Century Therapeutics?
- They were −$0.14 in fiscal 2025, compared with −$1.61 in fiscal 2024.
- Where does Century Therapeutics rank in its sector by net income?
- It ranks 190th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Century Therapeutics come from?
- From the annual report (Form 10-K) that Century Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Century Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Century Therapeutics: the Century Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.